Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has changed the payment terms to its Cobroxin distribution agreement with XenaCare Holdings.
“In light of XenaCare’s recently launched television advertising campaign, we have decided to continue our relationship with XenaCare to help them build the Cobroxin brand,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As XenaCare’s advertising continues, we remain optimistic that Cobroxin will become better known among consumers. XenaCare’s management has already informed us of improving sales exposure due to their advertising campaign. We look forward to working closely with XenaCare as they continue their ongoing advertising support for Cobroxin,” he added.
Cobroxin is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Currently, Cobroxin is available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
- All Natural
- Long Lasting
In 2009, Nutra Pharma granted an exclusive license to XenaCare Holdings (OTCBB: XCHO) to market and distribute Cobroxin in the United States.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company’s Cobroxin distribution contract with XenaCare Holdings should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.